-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Darolutamide in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Darolutamide in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Darolutamide in Triple-Negative Breast Cancer (TNBC) Drug Details: Darolutamide (Nubeqa)...
-
Company Insights
Innovation and Patenting activity of Orion Corp Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Orion Corp Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Darolutamide in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Darolutamide in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Darolutamide in Prostate Cancer Drug Details: Darolutamide (Nubeqa) is a nonsteroidal antiandrogen...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Darolutamide in Metastatic Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Darolutamide in Metastatic Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Darolutamide in Metastatic Prostate Cancer Drug Details: Darolutamide (Nubeqa) is a...
-
Thematic Analysis
Pharma M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Pharma Sector
-
Company Insights
Innovation and Patenting activity of Orion Holdings Corp Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Orion Holdings Corp Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of Orion Engineered Carbons GmbH Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Orion Engineered Carbons GmbH Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...